AB154 Combined With AB122 for Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma
will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and
Cohort B (surgical patient cohort).
Cohort A: Eligible patients will be sequentially enrolled to receive intravenous AB154
combined with AB122 (N=6). AB154 will be given at a dose of 10 mg/kg and AB122 will be given
at a dose of 240 mg (flat).
Cohort B: Expansion surgical cohort. The purpose of cohort B is to provide an additional
safety evaluation of AB154 + AB122 as well as tissue and blood for exploratory ancillary
studies investigating the effects of AB154 + AB122 in the tumor and tumor microenvironment. A
total of 40 patients will be enrolled in this cohort.